Denali Therapeutics Inc. logo

Denali Therapeutics Inc.

NASDAQ:DNLI

Overview | Financials
Company Name Denali Therapeutics Inc.
Symbol DNLI
Currency USD
Price 29.6
Market Cap 4,237,684,000
Dividend Yield 0%
52-week-range 14.56 - 32.132
Industry Biotechnology
Sector Healthcare
CEO Dr. Ryan J. Watts Ph.D.
Website https://www.denalitherapeutics.com

An error occurred while fetching data.

About Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

Related Stocks

Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc.

PCRX

17.7 USD

LifeStance Health Group, Inc. logo

LifeStance Health Group, Inc.

LFST

7.68 USD

STAAR Surgical Company logo

STAAR Surgical Company

STAA

31.46 USD

Telesis Bio, Inc. logo

Telesis Bio, Inc.

TBIO

1.11 USD

Roivant Sciences Ltd. logo

Roivant Sciences Ltd.

ROIV

11.76 USD

Neogen Corporation logo

Neogen Corporation

NEOG

15.78 USD

Privia Health Group, Inc. logo

Privia Health Group, Inc.

PRVA

22.53 USD

Progyny, Inc. logo

Progyny, Inc.

PGNY

16.53 USD

Financials

Numbers are in millions USD

Numbers are in millions USD